Your browser doesn't support javascript.
loading
First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.
Shimomura, Akihiko; Yamamoto, Noboru; Kondo, Shunsuke; Fujiwara, Yutaka; Suzuki, Shigenobu; Yanagitani, Noriko; Horiike, Atsushi; Kitazono, Satoru; Ohyanagi, Fumiyoshi; Doi, Toshihiko; Kuboki, Yasutoshi; Kawazoe, Akihito; Shitara, Kohei; Ohno, Izumi; Banerji, Udai; Sundar, Raghav; Ohkubo, Shuichi; Calleja, Elizabeth M; Nishio, Makoto.
Afiliação
  • Shimomura A; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Yamamoto N; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Kondo S; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan. nbryamam@ncc.go.jp.
  • Fujiwara Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Suzuki S; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Yanagitani N; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Horiike A; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Kitazono S; Department of Ophthalmic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Ohyanagi F; Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Doi T; Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Kuboki Y; Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Kawazoe A; Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Shitara K; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Ohno I; Department of Experimental Therapeutics, National Cancer Center Hospital East, Chiba, Japan.
  • Banerji U; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Sundar R; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Ohkubo S; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Calleja EM; Department of Hepatobiliary Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Nishio M; Clinical Pharmacology and Trials, The Institute of Cancer Research and The Royal Marsden, London, United Kingdom.
Mol Cancer Ther ; 18(3): 531-540, 2019 03.
Article em En | MEDLINE | ID: mdl-30679388
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Benzamidas / Carcinoma Pulmonar de Células não Pequenas / Proteínas de Choque Térmico HSP90 / Tumores do Estroma Gastrointestinal Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Asia / Europa Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Benzamidas / Carcinoma Pulmonar de Células não Pequenas / Proteínas de Choque Térmico HSP90 / Tumores do Estroma Gastrointestinal Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Asia / Europa Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão